1. Home
  2. SSBI vs CGTX Comparison

SSBI vs CGTX Comparison

Compare SSBI & CGTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

SSBI

Summit State Bank

N/A

Current Price

$13.22

Market Cap

91.6M

Sector

Finance

ML Signal

N/A

CGTX

Cognition Therapeutics Inc.

HOLD

Current Price

$1.05

Market Cap

79.6M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
SSBI
CGTX
Founded
1982
2007
Country
United States
United States
Employees
103
N/A
Industry
Major Banks
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
91.6M
79.6M
IPO Year
N/A
2021

Fundamental Metrics

Financial Performance
Metric
SSBI
CGTX
Price
$13.22
$1.05
Analyst Decision
Strong Buy
Analyst Count
0
3
Target Price
N/A
$3.33
AVG Volume (30 Days)
6.7K
673.7K
Earning Date
04-28-2026
05-06-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
62.79
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$13.23
N/A
Revenue Growth
N/A
N/A
52 Week Low
$10.35
$0.55
52 Week High
$14.00
$3.83

Technical Indicators

Market Signals
Indicator
SSBI
CGTX
Relative Strength Index (RSI) 49.20 51.96
Support Level $12.70 $1.02
Resistance Level $13.83 $1.19
Average True Range (ATR) 0.28 0.07
MACD 0.04 0.03
Stochastic Oscillator 69.17 62.96

Price Performance

Historical Comparison
SSBI
CGTX

About SSBI Summit State Bank

Summit State Bank provides various banking products and services to individuals and businesses in Sonoma County, California. It offers personal and business checking, money market, sweep, savings, and demand accounts; time certificates of deposit; and specialized deposit accounts, such as professional, small business packaged, tiered, and retirement plan accounts. The company also provides loans, including commercial loans and leases; lines of credit; commercial real estate, small business administration, residential mortgage, and construction loans; home equity lines of credit; and term and equipment loans, as well as loans to agriculture-related businesses.

About CGTX Cognition Therapeutics Inc.

Cognition Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the discovery and development of small-molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system (CNS) and retina. It aims to develop disease-modifying therapies for patients with these disorders. Its product candidate, zervimesine (CT1812), is an orally delivered small molecule designed to protect neuronal synapses by preventing the binding of oligomers of pathogenic proteins, including beta-amyloid and alpha-synuclein. These protein oligomers have been linked to the progression of degenerative diseases such as Alzheimer's disease (AD) and dementia with Lewy bodies (DLB).

Share on Social Networks: